RT Journal Article
SR Electronic
T1 Glycoproteome remodelling in MLL-rearranged B-cell precursor acute lymphoblastic leukemia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.25.21259296
DO 10.1101/2021.06.25.21259296
A1 Oliveira, Tiago
A1 Zhang, Mingfeng
A1 Joo, Eun Ji
A1 Abdel-Azim, Hisham
A1 Chen, Chun-Wei
A1 Yang, Lu
A1 Chou, Chih-Hsing
A1 Qin, Xi
A1 Chen, Jianjun
A1 Alagesan, Kathirvel
A1 Almeida, Andreia
A1 Jacob, Francis
A1 Packer, Nicolle H
A1 von Itzstein, Mark
A1 Heisterkamp, Nora
A1 Kolarich, Daniel
YR 2021
UL http://medrxiv.org/content/early/2021/09/02/2021.06.25.21259296.abstract
AB B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with mixed-lineage leukemia gene rearrangement (MLL-r) is a poor-prognosis subtype for which additional therapeutic targets are urgently needed. Currently no multi omics data set for primary MLL r patient cells exists that integrates transcriptomics, proteomics and glycomics to gain an inclusive picture of theranostic targets.Methods We have integrated transcriptomics, proteomics and glycomics to i) obtain the first inclusive picture of primary patient BCP-ALL cells and identify molecular signatures that distinguish leukemic from normal precursor B-cells and ii) better understand the benefits and limitations of the applied technologies to deliver deep molecular sequence data across major cellular biopolymers.Results MLL-r cells feature an extensive remodelling of their glycocalyx, with increased levels of Core 2-type O-glycans and complex N-glycans as well as significant changes in sialylation and fucosylation. Notably, glycosaminoglycan remodelling from chondroitin sulfate to heparan sulfate was observed. A survival screen, to determine if glycan remodelling enzymes are redundant, identified MGAT1 and NGLY1, essential components of the N-glycosylation/degradation pathway, as highly relevant within this in vitro screening. OGT and OGA, unique enzymes that regulate intracellular O-GlcNAcylation, were also indispensable. Transcriptomics and proteomics further identified Fes and GALNT7-mediated glycosylation as possible therapeutic targets. While there is overall good correlation between transcriptomics and proteomics data, we demonstrate that a systematic combined multi-omics approach delivers important diagnostic information that is missed when applying a single omics technology.Conclusions Apart from confirming well-known MLL-r BCP-ALL glycoprotein markers, our integrated multi-omics workflow discovered previously unidentified diagnostic/therapeutic protein targets.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by Leukemia Lymphoma Society (LLS) New Idea Award 2016/2017 (to N.H.), Civic Solutions Inc and Australian Research Council Future Fellowship FT160100344 (to D.K.), and the Griffith University Postgraduate Research Scholarship (GUPRS) (to T.O.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All human specimen collection protocols were reviewed by Childrens Hospital Los Angeles Institution Review Board (IRB) and Committee on Clinical Investigations (CCI). Protocols for collection were approved and found to be in compliance with ethical practices by the Childrens Hospital Los Angeles Institution Review Board and Committee on Clinical Investigations. All specimens were de-identified/anonymized before acquisition for research. The specimens were collected as leftover specimens that were initially collected for clinical diagnostic purposes and were discarded as medical waste when no longer needed for clinical purposes.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGlycomics data can be access on GlycoPOST using the following credentials: URL: https://glycopost.glycosmos.org/preview/192552055960853e1fc17f0 PIN code: 5775 Proteomics data can be accessed and reviewed on PRIDE using the following credentials: URL: https://www.ebi.ac.uk/pride Project Name: Altered glycoproteome of MLL-rearranged B-cell precursor acute lymphoblastic leukemia The Transcriptomics data has been deposited in GEO, accession Nr. GSE176364: Go to https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE176364, Enter token mnidkuosnzavxer Project accession: PXD025354 Username: reviewer_pxd025354@ebi.ac.uk Password: FldtRJ8T https://glycopost.glycosmos.org/preview/192552055960853e1fc17f0 https://www.ebi.ac.uk/pride https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE176364